BriaCell Therapeutics Corp. Warrant - BCTXW STOCK NEWS

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has appointed immunologist Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. Kharazi, co-inventor of Bria-IMT™, brings over 30 years of expertise in immunotherapy, having held prominent roles in various institutions and holds multiple patents. This strategic addition is expected to enhance BriaCell’s efforts in developing targeted immunotherapies for advanced breast cancer, as noted by President & CEO Bill Williams, highlighting Kharazi’s knowledge as a significant asset.

BriaCell Therapeutics Corp. (BCTX, BCTXW) announces the appointment of Dr. Giuseppe Del Priore as Chief Medical Officer, effective immediately. He will manage clinical and regulatory aspects of ongoing and future trials, including a Phase I/IIa study of Bria-IMT™ combined with checkpoint inhibitors in advanced breast cancer patients. Dr. Del Priore brings over 25 years of oncology experience and has held leadership roles in clinical trials management. His appointment is expected to advance BriaCell's mission to provide innovative therapies for cancer patients with limited options.

BriaCell Therapeutics (BCTX, BCTXW) has been selected to present at the AACR Annual Meeting 2022, showcasing its innovative cancer immunotherapy. The company also continues its corporate buyback program, having repurchased over 1 million shares and warrants since its inception. Additionally, insiders plan to individually acquire approximately 1.59 million shares, representing 10% of the company's common shares. With approximately $52 million in cash and no debt, BriaCell aims to enhance shareholder value through these strategic initiatives.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that all resolutions at the Annual and Special Meeting of Shareholders held on January 18, 2022, were approved. This includes the election of directors, setting the number of directors at seven, re-appointment of auditors MNP LLP, approval of the stock option plan, and an amendment to create a new class of subordinate voting shares. The voting results showed strong support, with director nominees receiving over 97% approval. Detailed voting results are filed on SEDAR.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that its common shares will start trading on the Toronto Stock Exchange (TSX) on December 31, 2021. Concurrently, the shares will be de-listed from the TSX Venture Exchange. The normal-course issuer bid (NCIB) will continue under the new trading venue. The average daily trading volume prior to the NCIB was 15,073 shares, with a daily purchase limit of 3,768 shares on the TSX. BriaCell focuses on targeted immunotherapies for advanced breast cancer and other malignancies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces insider intentions to acquire approximately 1.59 million common shares, representing 10% of the company's outstanding shares, starting January 31, 2022. Concurrently, the corporate buyback program continues, with 501,703 shares and 143,236 warrants repurchased to date. The company has raised $5.1 million from warrant exercises since November 1, 2021. With a cash balance of $55.5 million and no debt, BriaCell is well-positioned to pursue its cancer immunotherapy growth plans while enhancing shareholder value through these strategies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented clinical results for its immunotherapy candidate Bria-IMT™ at the 2021 San Antonio Breast Cancer Symposium. The analysis included data from 34 advanced breast cancer patients treated with Bria-IMT™, with a focus on safety and efficacy. Key findings highlighted a disease control rate of 25% and 33% for monotherapy and combination studies, respectively. Notably, complete tumor reductions were observed in patients with HLA matches and Grade I/II tumors, suggesting potential targeted treatment efficacy.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced that the Mary Crowley Cancer Research Center in Dallas, Texas, is now screening advanced breast cancer patients for a Phase I/IIa trial combining BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitors. Dr. Minal Barve will act as Principal Investigator. Additional sites in California and Kansas are also enrolling patients. This study aims to evaluate treatment effectiveness, with previous results showing an average survival of 12 months, significantly better than historical comparisons.

BriaCell Therapeutics Corp. (BCTX, BCTXW) has successfully repurchased 202,425 common shares and 70,246 warrants as part of its buyback program, aimed at enhancing shareholder value. The company is authorized to buy back up to 1,341,515 common shares and 411,962 warrants over the next 12 months. With a cash balance of US$57.3 million, BriaCell is well-positioned to advance its cancer immunotherapy strategies while executing this buyback. Additionally, Dr. William V. Williams, the CEO, will present at various upcoming conferences, underscoring the company's commitment to growth.